Hillhouse-Backed Genor Seeks Up to $1 Billion Valuation
(Bloomberg) -- Genor Biopharma Co. is seeking to raise about $100 million from private investors to fuel growth ahead of a potential initial public offering for the Chinese drugmaker, according to people familiar with the matter.
The company, backed by affiliates of private equity firm Hillhouse Capital, could reach a valuation of as much as $1 billion after the fundraising round, the people said, asking not to be identified because the deliberations are private. The Shanghai-based company is working with financial advisers on the private round, which will also help diversify its investor base, the people said.
Discussions are ongoing and no final decision on fundraising has been made, the people said. An IPO could follow in coming years, they said. A representative for Hillhouse declined to comment. Phone calls to Genor's headquarters went unanswered and a representative for the company didn't immediately respond to an email seeking comment.
Founded in 2007, Genor is developing and commercializing therapeutic antibodies to fight cancer and other diseases, according to its website. It has more than 10 products in its research-and-development pipeline. The company is also seeking to form partnerships to add to its pipeline and accelerate product development and commercialization. The website wasn't available on Tuesday with a notice saying it's “under construction.”
To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Crystal Tse in New York at ctse44@bloomberg.net
To contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, ;Liana Baker at lbaker75@bloomberg.net, Daniel Taub
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.